Early Breast Cancer Clinical Trials

15 recruiting

Early Breast Cancer Trials at a Glance

25 actively recruiting trials for early breast cancer are listed on ClinicalTrialsFinder across 6 cities in 24 countries. The largest study group is Not Applicable with 8 trials, with the heaviest enrollment activity in Dresden, Essen, and Beijing. Lead sponsors running early breast cancer studies include Novartis Pharmaceuticals, Xijing Hospital, and Dr David Joske (Chief Investigator).

Browse early breast cancer trials by phase

Treatments under study

About Early Breast Cancer Clinical Trials

Looking for clinical trials for Early Breast Cancer? There are currently 15 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Early Breast Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Early Breast Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 25 trials

Recruiting
Phase 3

Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

Early Breast Cancer
Novartis Pharmaceuticals1,400 enrolled205 locationsNCT05827081
Recruiting
Not Applicable

Luminal Breast Cancer Cryoablation

Breast CancerBreast Cancer (Early Breast Cancer)
Lucía Graña López140 enrolled1 locationNCT07447414
Recruiting

Patient Relevant Outcomes Improvement Program in High Risk Hormone Receptor Positive (HR+) Breast Cancer

HR+/HER2- Early Breast Cancer
Institut fuer Frauengesundheit200 enrolled1 locationNCT07531693
Recruiting

Real-life Evaluation of Endopredict® in Early HR+/HER2- Breast Cancer

HER2-negative Breast CancerBreast Cancer (Early Breast Cancer)Breast Cancer Survivors+2 more
Assistance Publique - Hôpitaux de Paris1,000 enrolled1 locationNCT07379918
Recruiting

Adherence to Aromatase Inhibitors ± Abemaciclib Treatment in Patients With Early-stage HER2-negative Breast Cancer

HER2-negative Breast CancerEarly Breast CancerHormone Receptor Positive Tumor
Institute of Oncology Ljubljana319 enrolled1 locationNCT06650423
Recruiting
Not Applicable

Tailored Exercise to Reduce Aromatase Inhibitor Associated Musculoskeletal Symptoms

Patients With Early Breast Cancer Who Initiating Adjuvant Aromatase Inhibitor
Mahidol University206 enrolled1 locationNCT07448558
Recruiting
Phase 2

A Study on the Use of Fluzoparib Combined With Chemotherapy for Neoadjuvant Treatment of HRD-positive, HR+/HER2- Breast Cancer

HR+/HER2- Early Breast Cancer
Xijing Hospital28 enrolled1 locationNCT07162051
Recruiting
Not Applicable

Breast Cancer Organelle Properties and Protein Expression Atlas in the Three Immunohistochemical Subtypes of Breast Cancers

Metastatic Breast CancerEarly Breast Cancer
Institut Claudius Regaud1,050 enrolled1 locationNCT07233928
Recruiting
Not Applicable

Evaluation of the Effectiveness of Managing Chemotherapy Side Effects Using ePRO and a Standardized Telenursing Program for Cancer Patients

Advanced Breast CancerEarly Breast CancerAdvanced Lung Cancer+5 more
Ulsan University Hospital414 enrolled5 locationsNCT07405931
Recruiting

RWE Non-Interventional Prospective Study of Ribociclib Effectiveness and Safety in Patients With HR+/HER2- Early Breast Cancer in Saudi Arabia

HR+/HER2- Early Breast Cancer
Novartis Pharmaceuticals177 enrolled2 locationsNCT06797531
Recruiting

Praegnant Breast Cancer: Early/Advanced/Metastatic

Breast Cancer (Early Breast Cancer)Advanced/Metastatic Breast Cancer
University Hospital Tuebingen13,500 enrolled61 locationsNCT02338167
Recruiting

Validation of the Oncoliq Test for the Early Detection of Breast Cancer.

Breast Cancer FemaleBreast Cancer DetectionBreast Cancer Early Stage Breast Cancer (Stage 1-3)+4 more
Oncoliq US Inc300 enrolled1 locationNCT07331506
Recruiting
Phase 2

Mediterranean Diet and Inequality in Early Breast Cancer

Early Breast Cancer
Esbjerg Hospital - University Hospital of Southern Denmark105 enrolled2 locationsNCT07007169
Recruiting
Not Applicable

A Prospective CohorT Study of HandX - Assisted ENdoscopic MAstectomy: Feasibility and Safety (ATHENA I Study)

Breast CancerBreast NeoplasmsEarly Breast Cancer+5 more
Vasileios Kalles15 enrolled1 locationNCT07292246
Recruiting
Not Applicable

A Study on the Treatment of Early Small Breast Cancer With Ultrasound-guided Vacuum-assisted Excision Combined With Surgery

Breast Cancer (Early Breast Cancer)
Xijing Hospital120 enrolled1 locationNCT07071402
Recruiting

Hypofractionated Radiotherapy With Concomitant Tumor Bed Boost for Breast Cancer

Early Breast CancerDuctal Breast Carcinoma In Situ
National Taiwan University Hospital315 enrolled2 locationsNCT06984250
Recruiting
Not Applicable

Impact of "Targeted" Nutritional Apport and Exercise on the Modulation of Metabolic and Immune-related Gene Expression Signatures in Early Breast Cancer (eBC) Patients Candidate to Neoadjuvant Therapy (NAT)

Early Breast CancerNeoadjuvant Treatment
University of Eastern Piedmont160 enrolled1 locationNCT06928701
Recruiting

Optimising patient positioning for accelerated partial breast radiotherapy with the Integrated Magnetic Resonance Linear Accelerator

Early Breast Cancer
Jenna Dean, ONJ Centre, Austin Health30 enrolled1 locationACTRN12624000679583
Recruiting
Phase 2

Efficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast Cancer

Early Breast Cancer
The First Affiliated Hospital with Nanjing Medical University1,163 enrolled1 locationNCT06341894
Recruiting
Phase 3

EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast Cancer

HER2 Positive Early Breast Cancer
Fudan University1,406 enrolled1 locationNCT05883852